The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•4 May 2026•

1 min read

FDA Accepts Opus Genetics Gene Therapy Program into RDEP Initiative

Key Facts

1Opus Genetics announced that its OPGx-LCA5 gene therapy program has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program.

Opus Genetics has announced that its OPGx-LCA5 gene therapy program has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program. This strategic initiative is designed to provide a framework for using novel evidence principles to support the development and registration of therapies for rare inherited retinal diseases. By participating in the RDEP program, Opus Genetics gains a structured pathway to accelerate its clinical development timeline. This regulatory milestone is viewed as a positive signal for the clinical-stage biotech company, highlighting its commitment to addressing unmet medical needs. While RDEP acceptance represents a procedural advancement rather than final product approval, it strengthens the company's regulatory standing. Market participants are closely watching the progress of this therapy as it moves through the FDA's specialized programs.

Sources: